50 Years of Monoclonal Antibody Technology: What’s Next? - Research Horizons
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
This article is an excerpt. To read the full content, visit the original source. Research Horizons
Related articles

Investigational FXI Monoclonal Antibodies Show Early Promise for Thrombosis - DocWireNews
The investigational factor XI (FXI) monoclonal antibodies amrecibart and cenvacibart demonstrated successful anticoagulation with a favorable safety profile in preclinical and phase 1 clinical studies, representing a novel treatment strategy for patients with thrombosis. The results were published in Blood by Dan Chalothorn, PhD, of Regeneron Pharmaceuticals, and colleagues. The research team first compared the mechanisms and coagulation effects of amrecibart and cenvacibart with other FXI-targeted monoclonal antibodies in both human and nonhuman primate plasma using an in vitro functional clotting assay.1Targeting the Intrinsic PathwayWith unique FXI/FXIa-binding mechanisms, amrecibart and cenvacibart address an unmet need for novel treatments with a favorable risk-benefit profile because current standard-of-care anticoagulants carry a high risk for bleeding. Cenvacibart and amrecibart block FXI activity by targeting the catalytic domain and the apple 2 domain of FXI/FXIa, respectively. Although standard-of-care anticoagulants target the extrinsic coagulation pathway, these monoclonal antibodies specifically target the intrinsic coagulation pathway.

Walid Kamoun Highlights Next-Generation In Vivo Antibody–ADC Click Technology - Oncodaily
“In all the innovative ADC approaches, this paper might reflect a next-next generation approach. Simó et al., in Nature, presents an In Vivo antibody ADC click technology. The design is bioorthogonal chemistry. A therapeutic antibody is conjugated with trans-cyclooctene, an ADC with tetrazine. The two are given sequentially and ligate in vivo after systemic delivery, forming a functional antibody-ADC click construct at the tumour.

Gemini's Personal Intelligence is coming to cars - Ars Technica
Google kicked off 2026 with the addition of Personal Intelligence to Gemini, allowing its AI to pull in more of your data to formulate answers. It started as a paid feature but eventually came to all Gemini users. However, this feature wasn’t available in the car until now. Google is rolling out Personal Intelligence to Android Auto and Google Built-in, and it is still, thankfully, an optional feature. As Google points out, a generative AI’s outputs are better “when it knows the world and knows you,” which is correct in an uncomfortable sort of way. The more context you can provide to a model, the better the output will be at the end of the token shuffle. Since Google has so much of your data already, it sees Personal Intelligence as a differentiator versus other AI systems. You don’t have to provide the AI context because it already has it from apps like Gmail and Calendar.
0 comments
No comments yet. Be the first to share your thoughts!